American Cancer Society BrightEdge
Overview
BrightEdge is the innovation, impact investment and venture capital arm of the American Cancer Society. Today, our donor-funded ACS Impact Venture Fund (AIVF) invests in for-profit, early-stage compan…
Investment Focus
- Early-stage companies developing cancer-focused therapeutics, diagnostics, devices, and technologies
Portfolio Companies
Reach American Cancer Society BrightEdge directly
Verified work email, phone and LinkedIn for the full team — one spreadsheet, one payment, yours to keep.
Unlock full contacts →Frequently asked questions about American Cancer Society BrightEdge
What sectors does American Cancer Society BrightEdge invest in?
American Cancer Society BrightEdge invests in Healthcare, Digital Health, Pharmaceuticals, Medical Devices, Diagnostics and Biotechnology, and is based in United States. American Cancer Society BrightEdge is listed as a venture capital in the ConnectSafely investor database.
What stage does American Cancer Society BrightEdge invest at?
American Cancer Society BrightEdge backs companies at Seed, Early Stage, Series A, Series B, Growth and Late Stage, writing cheques of 1M - 50M.
Which regions does American Cancer Society BrightEdge invest in?
American Cancer Society BrightEdge invests across United States.
What companies has American Cancer Society BrightEdge invested in?
American Cancer Society BrightEdge's portfolio includes Checkmate Pharmaceuticals, Cloverleaf Bio and Persephoni BioSciences LLC.
How do I contact American Cancer Society BrightEdge?
American Cancer Society BrightEdge's contact details — including phone and LinkedIn — are listed in the ConnectSafely investor database, along with its website and the LinkedIn profiles of the team.
Last updated · Source: ConnectSafely investor database
